Francesca Barone
Chief Scientific Officer Candel Therapeutics
Seminars
Wednesday 18th February 2026
Integration of Biomarkers & Imaging to Define Patient Response in a Phase I/II Clinical Trial
11:30 am
- Outlining a strategy for integrating diverse data streams, from molecular biomarkers to advanced imaging, to create a unified view of patient response
- Discussing how real-time insights from biomarkers and imaging can inform dynamic adjustments to drug dosage and treatment schedules, moving beyond traditional safety metrics
- Exploring how this integrated approach can provide a more robust and evidence-based foundation for making critical decisions about advancing the drug to a larger trial
Tuesday 17th February 2026
Harnessing Omics Data & Molecular Subtyping to Inform Patient Stratification in Clinical & Translational Strategies in Glioblastoma Drug Development
8:00 am
- Join this workshop to deepen your understanding of how omics approaches and molecular subtyping are used to stratify glioblastoma patients and define target populations for new therapies
- Examining the strategic integration of multi-omics including genomics, transcriptomics, proteomics and epigenomics for a more comprehensive and clinically actionable GBM classification system
- Identifying and validating specific molecular features as robust markers for defining GBM subtypes with prognostic and predictive value
- Leveraging molecular subtyping further down the line in development to design biomarker-driven clinical trials to enrich patient experience and improve trial efficiency
- Identifying and validating novel biomarkers with a focus on their identification in discovery
- Looking towards personalized GBM treatment where therapy selection is guided by a patient’s molecular profile
Wednesday 18th February 2026
Driving the Use of Biomarker-Based Enrollment in GBM trials to Accelerate Clinical Success & Improve Patient Outcomes
1:30 pm
- Addressing the lack of analysis of molecular data in current enrolment protocols for GBM trials
- Discussing strategies to incorporate biomarker-based enrolment given the rise of personalized therapies
- Establishing the efficacy of targeted treatments in recurrent GBM to accelerate the delivery of peronalized therapies
